Literature DB >> 24009964

Comparison of sensitivity and specificity of anti-CCP and anti-MCV antibodies in an Iranian cohort of patients with rheumatoid arthritis.

Behnaz Yousefghahari1, Saman Alhooei, Mohammad Jafar Soleimani-Amiri, Ardeshir Guran.   

Abstract

UNLABELLED: Background : Anti-CCP is a test commonly used for the diagnosis of rheumatoid arthritis. The aim of this study was to determine the diagnostic values of ACCP compared to anti-MCV in rheumatoid arthritis patients in north of Iran.
METHODS: The serum samples of 150 RA patients and 75 controls, with the mean age of 49.6+11.8 and 48.8+12 years respectively, were tested using the commercially available ELISA kits for ACCP and anti-MCV. Sensitivity, Specificity were determined and Roc curve were used for comparison between these two groups.
RESULTS: The sensitivity of ACCP versus anti-MCV was 85% and 81%, respectively. Specificity was 96% and 95%, respectively. In the RA patients, ACCP was positive in 127 (84.7%) and anti MCV in 121 (80.7%) cases. In the control group, these parameters were positive in 3 (4%) and 4 (5.3%) (p<0.0001 and p<0.0001, respectively). The correlation coefficient for ACCP and anti-MCV was calculated at 0.63 (p<0.001). The area under the curve for ACCP was 0.941±0.015 (p<0.001), anti-MCV was 0.902±0.02 (p<0.001). The measure of agreement (Kappa) for these variables was 0.81. In these patients, there was no correlation between DAS28 and the positivity of these tests.
CONCLUSION: It was concluded, compared to ACCP, anti-MCV has approximately the same accuracy for the diagnosis of rheumatoid arthritis and it does not have additional value.

Entities:  

Keywords:  ACCP; Anti-MCV; Rheumatoid arthritis

Year:  2013        PMID: 24009964      PMCID: PMC3755833     

Source DB:  PubMed          Journal:  Caspian J Intern Med        ISSN: 2008-6164


  16 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

Review 2.  Rheumatoid arthritis.

Authors:  David L Scott; Frederick Wolfe; Tom W J Huizinga
Journal:  Lancet       Date:  2010-09-25       Impact factor: 79.321

3.  Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.

Authors:  Linda Mathsson; Mohammed Mullazehi; Marius C Wick; Olof Sjöberg; Ronald van Vollenhoven; Lars Klareskog; Johan Rönnelid
Journal:  Arthritis Rheum       Date:  2008-01

4.  Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.

Authors:  Elena Bartoloni; Alessia Alunno; Onelia Bistoni; Nicola Bizzaro; Paola Migliorini; Gabriella Morozzi; Andrea Doria; Alessandro Mathieu; Milvia Lotzniker; Flavio Allegri; Valeria Riccieri; Claudia Alpini; Armando Gabrielli; Marilina Tampoia; Roberto Gerli
Journal:  Autoimmun Rev       Date:  2012-02-27       Impact factor: 9.754

5.  Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-hsp65): new biomarkers in ankylosing spondylitis.

Authors:  Nóra Bodnár; Zoltán Szekanecz; Zoltán Prohászka; Adám Kemény-Beke; Zsuzsanna Némethné-Gyurcsik; Katalin Gulyás; Gabriella Lakos; Sándor Sipka; Sándor Szántó
Journal:  Joint Bone Spine       Date:  2011-06-16       Impact factor: 4.929

6.  Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

Authors:  Michael P M van der Linden; Diane van der Woude; Andreea Ioan-Facsinay; E W Nivine Levarht; Gerrie Stoeken-Rijsbergen; Tom W J Huizinga; René E M Toes; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2009-08

7.  Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis.

Authors:  Rim Sghiri; Elyes Bouajina; Dhaker Bargaoui; Latifa Harzallah; Hosni Ben Fredj; Samar Sammoud; Ibtissem Ghedira
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

8.  Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.

Authors:  Lena Innala; Heidi Kokkonen; Catharina Eriksson; Erik Jidell; Ewa Berglin; Solbritt Rantapää Dahlqvst
Journal:  J Rheumatol       Date:  2008-04-01       Impact factor: 4.666

9.  Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.

Authors:  Pascale Nicaise-Roland; Leonor Nogueira; Christophe Demattei; Luc de Chaisemartin; Nathalie Rincheval; Martin Cornillet; Sabine Grootenboer-Mignot; Philippe Dieudé; Maxime Dougados; Alain Cantagrel; Olivier Meyer; Guy Serre; Sylvie Chollet-Martin
Journal:  Ann Rheum Dis       Date:  2012-05-12       Impact factor: 19.103

10.  Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.

Authors:  Pascale Nicaise Roland; Sabine Grootenboer Mignot; Alessandra Bruns; Margarita Hurtado; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Olivier Meyer; Sylvie Chollet Martin
Journal:  Arthritis Res Ther       Date:  2008-12-10       Impact factor: 5.156

View more
  5 in total

Review 1.  Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis.

Authors:  Y H Lee; S-C Bae; G G Song
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

2.  Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.

Authors:  Georgia Barouta; Christina G Katsiari; Ioannis Alexiou; Christos Liaskos; Areti Varna; Dimitrios P Bogdanos; Anastasios E Germenis; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2016-12-10       Impact factor: 2.980

3.  Immunodiagnostic significance of anti-RA33 autoantibodies in Saudi patients with rheumatoid arthritis.

Authors:  Jamil A Al-Mughales
Journal:  J Immunol Res       Date:  2015-03-25       Impact factor: 4.818

4.  Diagnostic value of high-frequency color Doppler ultrasonography examination in combination with anti-cyclic citrullinated peptide antibody testing in rheumatoid arthritis patients.

Authors:  Ming-Yu Wang; Xian-Bin Wang; Xue-Hui Sun; Feng-Li Liu; Sheng-Chuan Huang
Journal:  Exp Ther Med       Date:  2017-01-17       Impact factor: 2.447

5.  Antibodies to synthetic citrullinated peptide epitope correlate with disease activity and flares in rheumatoid arthritis.

Authors:  Sangita Khatri; Jonas Hansen; Kira Astakhova
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.